Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.
Also called NCT01976507
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 101 participants
- Registry
-
NCT01976507
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01976507. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (actual); primary completion 2016-12 (actual). Results posted on 2017-09-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
- Condition
- Atrial Fibrillation
- Condition
- Atrial Flutter
- Intervention (Drug)
- dabigatran etexilate mesylate
- Lead sponsor
- Vanderbilt University Medical Center
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct01976507- Content hash
3eaf9f6b916f9c9d822e3334831ec10f9d5be58c03c7681983f75aa4abed2bf7